SAB Biotherapeutics, Inc. announced the appointment of Erick Lucera, CFA, a veteran of the biotechnology and medical device industry, with over thirty years of financial, operational and investment experience, to the company's board of directors, effective April 4, 2023. Most recently, Mr. Lucera served as chief financial officer for AVEO Oncology, from January 2020 until February 2023. Subsequent to the close of AVEO's acquisition by LG Chem Ltd., he advised AVEO's management team through the transition.

Prior to his time at AVEO Oncology, Mr. Lucera held chief financial officer and other senior roles at several biotechnology and medical device companies. He was previously chief financial officer of Valeritas, where he led the company through multiple successful public offerings. Prior to Valeritas, Mr. Lucera served as chief financial officer, treasurer, and secretary of Viventia Bio (acquired by Eleven Biotherapeutics, Inc., now Sesen Bio).

He also previously served as vice president, corporate development at Aratana Therapeutics, where he helped grow the company's product pipeline through a series of acquisitions and in-licensing transactions financed through five public and private offerings of nearly $250 million. Early in his career, Mr. Lucera spent more than 15 years covering healthcare and the life sciences in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathalon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He began his career as a staff auditor and accountant at Price Waterhouse & Co.

(now PwC). Mr. Lucera holds a Certification in Public Health (CPH) from Harvard University, as well as an MS from Boston College and an MBA from Indiana University Bloomington. He earned his BS in accounting from the University of Delaware.

Additionally, Mr. Lucera currently holds a CFA designation. He previously held CMA and CPA designations, now expired.